Study finds dextromethorphan‐quinidine reduces agitation in Alzheimer's patients

A study using a sequential design with two 5‐week treatment stages has found that the combination of dextromethorphan hydrobromide and quinidine sulfate significantly reduced symptoms of moderate to severe agitation compared with placebo in a group of patients with Alzheimer's disease. The researchers found that this treatment generated minimal side effects relative to the side‐effect profiles of other drugs used to address agitation and aggression in Alzheimer's patients, including antipsychotics. Study results were published Sept. 22/29, 2015, in the Journal of the American Medical Association.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Geriatric Psychiatry Source Type: research